http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101524527-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2008-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101524527-B |
| titleOfInvention | TAT-HOXB4H recombinant protein and medical treatment constituent thereof as hematopoiesis irritant |
| abstract | The invention discloses a kind of TAT-HOXB4H recombinant protein as hematopoiesis irritant and medical treatment constituent thereof, relate to the HOXB4 recombinant protein that a kind of C-end contains histidine labelling. Solve the technical problem that yield of recombinant proteins is few and stability is poor obtained in prior art by culture fluid purification. The present invention promotes that hematopoietic stem cell is by the medical constituent of bone marrow mobilization to periphery blood, TAT-HOXB4H recombinant protein including at least an effective dose, the amount of protein is enough to increase the absolute number of hematopoietic stem cell in user bone marrow, thus promoting that hematopoietic stem cell mobilization is to the periphery blood of user. The present invention is in order to improve the medical constituent of the recovery time of patients with hematopoietic stem cells transplantation, radiation cure patient or patients undergoing chemotherapy, including at least the TAT-HOXB4H recombinant protein of an effective dose, the amount of this protein is enough to increase the absolute number of hematopoietic stem cell in user bone marrow. The present invention is applied to increase the number of the hematopoietic stem cell in bone marrow and in periphery blood. |
| priorityDate | 2008-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 228.